Optimizer System With ODOCOR II CCM™ Leads
Clinical Investigation of the ODOCOR II CCM™ Leads in Patients With Optimizer System Implant
1 other identifier
observational
200
3 countries
40
Brief Summary
The objective of the ODOCOR II CCM lead study is to evaluate the safety and useability of the ODOCOR II intra-cardiac lead specifically intended to deliver CCM as an accessory lead to the Optimizer IPG.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Mar 2021
Longer than P75 for all trials
40 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 11, 2021
CompletedFirst Posted
Study publicly available on registry
February 16, 2021
CompletedStudy Start
First participant enrolled
March 1, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2025
CompletedAugust 2, 2023
August 1, 2023
3.8 years
February 11, 2021
August 1, 2023
Conditions
Outcome Measures
Primary Outcomes (2)
Primary Safety endpoint
The primary safety endpoint is the incidence of lead-related complication free rate at 12 months post-index implantation procedure compared to the incidence previously described in the literature for pacing therapy leads.
12 months
Primary Efficacy endpoint
The total amount of CCM delivered to the cardiac tissue of the right ventricle (measured by CCM percentage) will be measured over a period of 12 months.
12 month
Secondary Outcomes (2)
Secondary Safety endpoint
12 month
Secondary Efficacy endpoint
12 month
Other Outcomes (1)
Additional Endpoints
at implant
Interventions
ODOCOR II CCM LEADS Implantation
Eligibility Criteria
The total investigation is expected to last approximately 3 years , including enrollment and follow-up periods. Four hundred (400) ODOCOR II CCM leads will be implanted in 200 eligible subjects from up to 40 sites in Europe
You may qualify if:
- Patient signed and dated informed consent form
- Male or non-pregnant female, aged 18 or older
- Left ventricular ejection fraction of 25-45% (inclusive)
- Diagnosed with NYHA Class III or IV heart failure
- Stated willingness to comply with all study procedures and availability for the duration of the study
- Medically stable and with no significant mental illness in the judgement of the principal investigator
You may not qualify if:
- Infiltrative or inflammatory cardiomyopathy (e.g. amyloid, hemochromatosis, myocarditis, hypertrophic cardiomyopathy, Fabry's disease, cardiac tumor)
- Primary heart failure due to uncorrected mitral valve disease, or mitral valve repair or clip within 3 months of the baseline testing visit.
- IV inotropes, hemofiltration, or any form of positive inotropic support within 30 days before the baseline testing visit, including continuous IV inotrope therapy
- Myocardial infarction within 3 months of the baseline testing visit.
- Undergone a CABG procedure within 3 months90 days or a PTCA procedure within 30 days of the baseline testing visit.
- Undergone a cardiac ablation procedure within 90 days prior to consent.
- Prior heart transplant or ventricular assist device
- Mechanical tricuspid valve
- Receiving cardiac resynchronization therapy (CRT) or indicated for Class I CRT implantation according to the ACCF/AHA/HRS guidelines for device-based therapy
- Currently on dialysis
- Currently undergoing active chemotherapeutic and/or radiation treatment for cancer
- Participating in another cardiac investigational device study at the same time
- Patient is in a vulnerable population (such as significant mental disability, prisoner) that in the judgement of the PI impedes ability to provide informed content.
- Expected lifespan of less than 12 months from time the baseline testing visit.
- Resting heart rate \>110 bpm at the time of the baseline testing visit
- +2 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Impulse Dynamicslead
Study Sites (40)
Klinik am Plattenwald
Heilbronn, Baden-Wurttemberg, 74177, Germany
St. Anna Krankenhaus
Sulzbach-Rosenberg, Bavaria, 92237, Germany
St. Josefs-Hospital Wiesbaden GmbH
Wiesbaden, Hesse, 65189, Germany
Elbe Klinikum Stade
Stade, Lower Saxony, 21682, Germany
Augusta-Kranken-Anstalt Bochum-Mitte
Bochum, North Rhine-Westphalia, 44791, Germany
Krankenhaus Marie-Hilf Stadtlohn
Stadtlohn, North Rhine-Westphalia, 48703, Germany
Herzzentrum Dresden
Dresden, Saxony, 01307, Germany
Klinikum Magdeburg
Magdeburg, Saxony-Anhalt, 39120, Germany
DRK Kliniken Berlin Koepenick
Berlin, 12559, Germany
Charité Berlin Campus Virchow
Berlin, 13353, Germany
Evangelisches Klinikum Bethel
Bielefeld, 33617, Germany
Regiomed Kliniken-Coburg
Coburg, Germany
SRH Krankenhaus Waltershausen-Friedrichroda
Friedrichroda, 99894, Germany
Marienhospital
Gelsenkirchen, 45886, Germany
Asklepios Klinik St. Georg
Hamburg, 20099, Germany
Schoen Klinik Hamburg Eilbek
Hamburg, 22081, Germany
Evangelisches Krankenhaus Herne
Herne, 44623, Germany
St. Marien-Hospital Klinikum Luenen
Lünen, D-44534, Germany
Universitaetsklinikum UMM
Mannheim, Germany
Niels-Stensen-Kliniken Marienhospital Osnabrück GmbH
Osnabrück, 49074, Germany
Azienda Ospedaliera Dei Colli-Monaldi
Naples, Campania, 80131, Italy
Ospedale "Sacra Famiglia" - Fatebenefratelli dell'
Erba, Lombardo Veneta, 22036, Italy
Ente Ecclesiastico Ospedale Generale Regionale "F.Miulli" Cardiologia e U.T.I.C.
Acquaviva delle Fonti, Italy
Ospedale C. e G. "Mazzoni"
Ascoli Piceno, 63100, Italy
Ospedale San Paolo, UOC Cardiologia ed UTIC
Bari, 70123, Italy
Azienda Ospedaliero Universitaria Consorziale - Policlinico di Bari U.O.C Cardiologia Ospedaliera
Bari, Italy
IRCCS Policlinico Sant'Orsola-Malpighi
Bologna, Italy
Azienda Ospedaliero-Universitaria di Cagliari
Cagliari, Italy
Azienda Sanitaria Provinciale di Cosenza "Ospedale di Castrovillari
Castrovillari, Italy
ASL TO 4 - Presidio Ospedaliero Riunito sede di Cirie
Cirié, Italy
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
Milan, 20122, Italy
Azienda Ospedaliera Universitaria Maggiore della Carita
Novara, 28100, Italy
Gruppo Synergo - Casa Di Cura Pierangeli
Pescara, 65124, Italy
Presidio Ospedaliero Sant'Andrea
Vercelli, 13100, Italy
Ospedale San Bortolo di Vicenza - Azienda UlSS 8 Berica
Vicenza, 36100, Italy
Complejo Hospitario Torrecardenas
Almería, 04009, Spain
Hospital Virgen de las Nieves
Granada, 18014, Spain
Hospital 12 de Octubre
Madrid, 28041, Spain
Hospital Puerta de Hierro
Madrid, 28222, Spain
Hospital Clinico U. de Santiago
Santiago de Compostela, 15706, Spain
Study Officials
- PRINCIPAL INVESTIGATOR
Stefano DeVivo, MD
Monaldi Hospital
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 11, 2021
First Posted
February 16, 2021
Study Start
March 1, 2021
Primary Completion
December 31, 2024
Study Completion
December 31, 2025
Last Updated
August 2, 2023
Record last verified: 2023-08
Data Sharing
- IPD Sharing
- Will not share